

## PRESIDENTE DEL CONGRESSO

Pierfranco Conte

## OSPITE INTERNAZIONALE

Chad Creighton

Dan L. Duncan Cancer Center -  
Baylor College of Medicine (Houston - USA)

## BOARD

Alberto Bottini

Luigi Dogliotti

Francesco Cognetti

Luca Gianni

Pierfranco Conte

Giorgio Mustacchi

Sabino De Placido

Paolo Pronzato

## SEGRETERIA ORGANIZZATIVA

OVER Srl

Via Pagliari, 4 - 26100 Cremona  
TEL 0372 23310 - FAX 0372 569605  
gloria.platti@overgroup.eu

IL CORSO È STATO ACCREDITATO PER LE SEGUENTI  
DISCIPLINE: ANATOMIA PATOLOGICA, BIOLOGIA,  
ONCOLOGIA E RADIOTERAPIA

CON IL CONTRIBUTO INCONDIZIONATO DI



The Aiom logo consists of the word 'Aiom' in a white, serif font, with a green and red graphic element resembling a stylized 'A' or a molecular structure to its left.

Con il patrocinio  
dell'Associazione Italiana di Oncologia Medica

A large, bright yellow and orange sparkler graphic is positioned in the upper right quadrant of the page, with its sparks radiating outwards against the blue background.

**bjclub**  
breastJournalClub

**29-30 NOVEMBRE 2013**

**PADOVA**  
HOTEL PLAZA  
C.so Milano, 40

# PROGRAMMA

**29 Novembre 2013**

**16:00**

Benvenuto e apertura lavori

**P.F. Conte, L. Dogliotti**

**16:15**

Presentazione e premiazione Chad Creighton

**P.F. Conte, A. Bottini**

**16:30**

Comprehensive molecular portraits of human breast tumours

**C. Creighton**

**17:30**

Discussione

**G. Mustacchi**

**18:30**

Conclusioni

**P.F. Conte**

**30 Novembre 2013**

**09:30**

**PRESENTAZIONE LAVORI UNDER 40**

Moderatori: **A. Berruti, M. Mottolose, S. De Placido**

Discussant: **L. Del Mastro**

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Presenter: **D. Generali**

G. Allevi, C. Strina, D. Andreis, V. Zanoni, L. Bazzola, S. Bonardi, C. Foroni, M. Milani, M.R. Cappelletti, F. Gussago, S. Aguggini, R. Giardini, M. Martinotti, S.B. Fox, A.L. Harris, A. Bottini, A. Berruti, D. Generali  
Br J Cancer. 2013 Apr 30;108(8):1587-92. doi: 10.1038/bjc.2013.1

Discussant: **A. Frassoldati**

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis.

M.V. Dieci, E. Barbieri, F. Piacentini, G. Ficarra, S. Bettelli, M. Dominici, P.F. Conte, V. Guarneri

Ann Oncol. 2013 Jan;24(1):101-8. doi

Presenter: **M. V. Dieci**

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2 positive breast cancer patients

Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF

Ann Oncol, 2013 Sep 7

Presenter: **V. Guarneri**

Discussant: **M. De Laurentiis**

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

Presenter: **M. Clavarezza**

M. Clavarezza, M. Turazza, E. Aitini, S. Saracchini, O. Garrone, A. Durando, S. De Placido, G. Bisagni, A. Levaggi, C. Bighin,

E. Restuccia, R. Scalamogna, A. Galli, L. Del Mastro

Breast. 2013 Apr 3

**10:30**

**NEW GENERATION OF TAXANES IN MBC: WORK IN PROGRESS**

Moderatori: **V. Adamo, M.T. Ionta, P. Pronzato**

Studio Effect - Evaluation of the efficacy and impact on patient functioning of two doses of nab-paclitaxel in elderly (>65 yrs) breast cancer patients

**E. Zafarana**

Studio SNAP (A randomized phase II study evaluating three different schedules of nab-paclitaxel as maintenance therapy in metastatic breast cancer)

**C. Tondini**

**11:15**

Pausa

**11:30**

**NEW GENERATION OF TAXANES I**

**N MBC: WORK IN PROGRESS**

Moderatori: **G. Arpino, G. Bianchini, F. Cognetti**

Studio ETNA - Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer

nab-paclitaxel 150 mg/m<sup>2</sup> day 1, 8, 15 for 4 cycles 28 days followed by AC or FEC for 4 cycles vs Weekly paclitaxel for 4 cycles followed by AC or FEC for 4 cycles both followed by surgery

**F. Puglisi**

Studio ABRAMYO - Phase I-II, multicenter open label study in patients with previously untreated metastatic breast cancer

Nab-paclitaxel 100 → 125 mg/ m<sup>2</sup> and with LDox 20 → 25 mg/ m<sup>2</sup> will be administered on days 1, 8, 15 of a 28-day cycle until disease progression

**P. Papaldo**

Studio TNACITY - Phase 2/3, multi-center, open-label, randomized study of weekly Nab-paclitaxel in combination with gemcitabine or carboplatin, vs gemcitabine / carboplatin, as first-line treatment in TNMBC

Abraxane 125mg/ m<sup>2</sup>, Gemcitabine 1000mg/ m<sup>2</sup>, Carboplatin AUC2 days 1,8 cycles 21 days

**V. Guarneri**

**13:15**

Round Table Board BJClub

**13:45**

Conclusioni e compilazione questionario ECM

**14:15**

Fine Lavori

**bjclub**  
breastjournalclub